Biotech giant Amgen Inc. is selling $1.5 billion in notes, its second large debt sale this year.

The Thousand Oaks company said in a regulatory filing late Monday that proceeds may be used for working capital, capital expenditures, refinancing outstanding debt, share buybacks, acquisitions and licensing activities.

IFR, a Thomson Reuters service, said the offering includes $900 million of 10-year notes, priced to yield 77 basis point over comparable U.S. Treasuries, and $600 million of 31-year bonds priced to yield 117 basis points more than Treasuries.

Citigroup, Goldman Sachs, and Morgan Stanley are joint book-running managers for the offering. Among the rating services, Moody’s rated the bonds A3, S&P rated them A+, and Fitch A.

The company in March sold $1 billion in 10- and 30-year notes, according to data compiled by Bloomberg.

Shares were up 50 cents, or less than 1 percent, to $54.94 in midday trading on the Nasdaq.